New: the free Stackhaus Compass research dashboard, upload your labs
Cognitive EnhancementIntermediateGray Area

Pinealon

Glu-Asp-Arg (EDR) Tripeptide Bioregulator

Low Dose
5 mg/day
Medium Dose
10 mg/day
Route
SubQ / Intranasal
Cycle Length
10–20 days, 1–2x/year

Mechanism of Action

Ultra-short synthetic tripeptide proposed to penetrate cells and interact with chromatin/regulatory proteins, modulating expression of genes involved in neuronal apoptosis (caspase-3), antioxidant defense, and neurotransmitter synthesis. In aged-rat models it reduces oxidative/free-radical markers and caspase-3 activity in brain tissue under hypoxic and hypothermic stress, and improves spatial learning performance (Morris water maze) more than the related peptide Cortexin.

Key Benefits

  • Reduced caspase-3 activity and oxidative stress markers in aged brain tissue (preclinical)
  • Improved spatial learning/memory performance in aged-animal models
  • Neuroprotection under hypoxic and hypothermic stress conditions (preclinical)
  • Positioned within a broader Khavinson short-peptide neuroprotective research program alongside Semax and Cortagen

Dosing Protocol

Low / Starting Dose
5 mg/day
Medium / Maintenance Dose
10 mg/day
Administration Route
SubQ / Intranasal
Half-Life
Minutes (rapidly degraded; downstream gene-expression effects persist beyond plasma clearance)
Frequency
Once daily during course
Cycle Length
10–20 days, 1–2x/year
Protocol Notes

Evidence base is substantially preclinical (aged-rat models) with far less human trial data than Epitalon or Semax from the same research lineage — treat efficacy claims accordingly.

Ideal Candidates

Cognitive-decline and healthy-aging research interest; most data is preclinical/animal, so expectations should be tempered relative to human-trial peptides.

Side Effects & Safety

No significant adverse effects reported in the largely animal and small Russian clinical literature; human safety data is limited outside Russia.

Regulatory Status

Gray Area

Not on the 503A bulks list. Part of the Khavinson short-peptide bioregulator line; no FDA approval status. Educational reference only.

Evidence & Citations

Frequently asked

What is Pinealon?+

Pinealon (Glu-Asp-Arg (EDR) Tripeptide Bioregulator) is a peptide studied for neuroprotection and learning & memory. Ultra-short synthetic tripeptide proposed to penetrate cells and interact with chromatin/regulatory proteins, modulating expression of genes involved in neuronal apoptosis (caspase-3), antioxidant defense, and neurotransmitter synthesis. In aged-rat models it reduces oxidative/free-radical markers and caspase-3 activity in brain tissue under hypoxic and hypothermic stress, and improves spatial learning performance (Morris water maze) more than the related peptide Cortexin.

What is the dosing protocol for Pinealon?+

Literature commonly references 5 mg/day (low) to 10 mg/day (maintenance) via SubQ / Intranasal, on a 10–20 days, 1–2x/year cycle. Educational reference only — a licensed Stackhaus Health provider sets any personalized protocol.

What is the regulatory status of Pinealon?+

Not on the 503A bulks list. Part of the Khavinson short-peptide bioregulator line; no FDA approval status. Educational reference only.

Where can I access Pinealon?+

Research-grade Pinealon is available through Stackhaus Research. For a personalized, provider-reviewed protocol, consult a licensed clinician through Stackhaus Health.

More in Cognitive Enhancement

Used in these stacks

Pinealon appears in 1 research protocol in the Stackhaus Academy library.

Written and reviewed by Stackhaus Academy Editorial Team · Last reviewed July 2026

Educational Only. This page is educational reference material, not medical advice. It does not establish a doctor-patient relationship and is not a substitute for individualized clinical guidance. Personalized protocols and clinical decisions are made through a licensed provider via Stackhaus Health.